{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-023167","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.750813+00:00","generated_at":"2026-05-26T11:22:39.159858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Outset Medical Q4 revenue $29.5M, beats guidance; 2025 outlook $115-125M revenue, high-30% gross margin","bullets":["Q4 revenue $29.5M (+3% QoQ, -3% YoY); full-year $113.7M, beating prior guidance.","Q4 GAAP gross margin 36.5% (37.7% non-GAAP), up 11pp YoY; recurring revenue up 21% to $83.9M in 2024.","Q4 net loss $25.6M ($0.49/sh) vs $38.6M ($0.77/sh) YoY; non-GAAP loss $19.3M ($0.37/sh).","Tablo installed base ~6,000 consoles (+10% in 2024); cash $162M at yr-end, ~$210M after Jan 2025 financing.","2025 guidance: revenue $115-125M, non-GAAP gross margin high-30% range; cash burn <$50M vs $103M in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-023167","json":"https://secwatch.observer/filing/0000950170-25-023167.json","markdown":"https://secwatch.observer/filing/0000950170-25-023167.md","text":"https://secwatch.observer/filing/0000950170-25-023167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025023167/0000950170-25-023167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025023167/om-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T11:22:39.159858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}